Showing results (11-20 of 307) with videos related to

Sort By:
Pageof 31
Clinical Parkinsonism & Related Disorders|February 19, 2025
Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson's diseaseStuart H Isaacson, Peter Jenner
The Journal of Clinical Psychiatry|December 2, 2020
Pharmacology and Evidence-Based Strategies for Current and Emerging Treatments for OFF Periods in Parkinson DiseaseRajesh Pahwa, Stuart H Isaacson
Vascular Health and Risk Management|April 15, 2014
Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopaStuart H Isaacson, Julia Skettini
Expert Opinion on Drug Safety|April 25, 2022
Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directionsStuart H Isaacson, Leslie Citrome
Journal of Parkinson'S Disease|January 14, 2020
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's DiseaseCaroline M Tanner, Rajesh Pahwa, Robert A Hauser, et al.
The Journal of Clinical Psychiatry|October 28, 2020
Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson DiseaseRajesh Pahwa, Stuart H Isaacson
Clinical Parkinsonism & Related Disorders|August 23, 2024
Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson's disease experiencing OFF episodes: A modified Delphi panelStuart H Isaacson, Richard Dewey, Robert A Hauser, et al.
Parkinsonism & Related Disorders|April 18, 2019
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's diseaseRobert A Hauser, Stuart H Isaacson, Aaron Ellenbogen, et al.
Degenerative Neurological and Neuromuscular Disease|August 1, 2022
Istradefylline for OFF Episodes in Parkinson's Disease: A US Perspective of Common Clinical ScenariosStuart H Isaacson, Sagari Betté, Rajesh Pahwa
Journal of Parkinson'S Disease|September 6, 2021
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 TrialsRobert A Hauser, Nobutaka Hattori, Hubert Fernandez, et al.
Pageof 31